| Neuren Pharmaceuticals Limited (NEU) ORDINARY FULLY PAID |
Health Care |
$2,112 |
Update - Notification of buy-back - NEU
|
13 Mar 2026 8:26AM |
$11.950 |
$16.660 |
risen by
39.41%
|
|
| Neuren Pharmaceuticals Limited (NEU) ORDINARY FULLY PAID |
Health Care |
$2,112 |
Update - Notification of buy-back - NEU
|
10 Mar 2026 8:40AM |
$11.680 |
$16.660 |
risen by
42.64%
|
|
| Neuren Pharmaceuticals Limited (NEU) ORDINARY FULLY PAID |
Health Care |
$2,112 |
Change of Director's Interest Notice - J Basile
|
6 Mar 2026 10:25AM |
$12.590 |
$16.660 |
risen by
32.33%
|
|
| Neuren Pharmaceuticals Limited (NEU) ORDINARY FULLY PAID |
Health Care |
$2,112 |
Update - Notification of buy-back - NEU
|
4 Mar 2026 8:42AM |
$12.560 |
$16.660 |
risen by
32.64%
|
|
| Neuren Pharmaceuticals Limited (NEU) ORDINARY FULLY PAID |
Health Care |
$2,112 |
Acadia confirms plan to request CHMP re-examination
|
3 Mar 2026 9:50AM |
$13.770 |
$16.660 |
risen by
20.99%
|
|
NEU - Price-sensitive ASX Announcement
Full Release
Key Points
- Acadia Pharmaceuticals plans to request CHMP re-examination for trofinetide.
- Trofinetide approved in the US, Canada, and Israel.
- CHMP refused approval citing limited treatment effect and study design issues.
- Neuren Pharmaceuticals supports re-examination.
- Trofinetide has been effective in approved markets.
- There is a substantial unmet medical need for Rett syndrome treatment in Europe.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Neuren Pharmaceuticals Limited (NEU) ORDINARY FULLY PAID |
Health Care |
$2,112 |
Investor presentation, 27 February 2026
|
27 Feb 2026 11:54AM |
$13.480 |
$16.660 |
risen by
23.59%
|
|
| Neuren Pharmaceuticals Limited (NEU) ORDINARY FULLY PAID |
Health Care |
$2,112 |
2025 royalty income A$65m, profit after tax A$30m
|
27 Feb 2026 9:59AM |
$13.440 |
$16.660 |
risen by
23.96%
|
|
NEU - Price-sensitive ASX Announcement
Full Release
Key Points
- Neuren reported A$65 million royalty income in 2025, up 15% from 2024.
- Profit after tax for 2025 was A$30 million.
- Cumulative income of A$510 million from DAYBUE® since 2023 launch.
- DAYBUE® 2025 net sales were US$391 million.
- NNZ-2591 clinical trials underway for Phelan-McDermid syndrome.
- A$296 million in cash and short-term investments at year-end 2025.
- Completed A$50 million share buy-back in 2025; new program begins March 2026.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Neuren Pharmaceuticals Limited (NEU) ORDINARY FULLY PAID |
Health Care |
$2,112 |
Appendix 4E and 2025 full year accounts
|
27 Feb 2026 9:53AM |
$13.440 |
$16.660 |
risen by
23.96%
|
|
NEU - Price-sensitive ASX Announcement
Full Release
Key Points
- Net profit after tax for 2025 was A$30.4 million, compared to A$142.0 million in 2024.
- Basic earnings per share for 2025 were A$0.2373.
- Total revenue for 2025 was A$84.8 million, a 63% decrease from 2024.
- Royalty income increased by 15% to A$64.6 million.
- Corporate and administrative costs for 2025 were A$6.2 million.
- Cash and short-term investments at the end of 2025 were A$296.1 million.
- The company executed a A$39.6 million share buy-back.
- Financial statements received an unqualified audit opinion.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Neuren Pharmaceuticals Limited (NEU) ORDINARY FULLY PAID |
Health Care |
$2,112 |
Acadia reports DAYBUE net sales for 2025 and 2026 guidance
|
26 Feb 2026 11:15AM |
$12.710 |
$16.660 |
risen by
31.08%
|
|
NEU - Price-sensitive ASX Announcement
Full Release
Key Points
- Acadia reported full year 2025 DAYBUE net sales of US$391 million, up 12% year-on-year.
- Q4 2025 DAYBUE net sales reached US$110 million, a 13% increase compared to Q4 2024.
- Neuren’s full year 2025 royalty income was A$65 million, a 15% increase from 2024.
- Acadia’s guidance for full year 2026 DAYBUE net sales is US$460 million to US$490 million.
- Neuren expects full year 2026 royalty income of A$70 million to A$77 million from DAYBUE.
- DAYBUE STIX powder formulation was approved in December 2025, with a full launch expected by Q2 2026.
- Phase 3 clinical trial of trofinetide ongoing in Japan with results expected between Q4 2026 and Q1 2027.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Neuren Pharmaceuticals Limited (NEU) ORDINARY FULLY PAID |
Health Care |
$2,112 |
Pause in Trading
|
26 Feb 2026 9:53AM |
$12.710 |
$16.660 |
risen by
31.08%
|
|
NEU - Price-sensitive ASX Announcement
Full Release
Key Points
- Neuren Pharmaceuticals Limited is listed with the security code NEU.
- A trading pause was announced for Neuren Pharmaceuticals Limited's securities.
- Further announcements from the company are anticipated.
- The announcement was made in compliance with ASX listings.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Neuren Pharmaceuticals Limited (NEU) ORDINARY FULLY PAID |
Health Care |
$2,112 |
Update - Notification of buy-back - NEU
|
13 Feb 2026 9:32AM |
$13.570 |
$16.660 |
risen by
22.77%
|
|
| Neuren Pharmaceuticals Limited (NEU) ORDINARY FULLY PAID |
Health Care |
$2,112 |
Notification of buy-back - NEU
|
11 Feb 2026 6:24PM |
$13.430 |
$16.660 |
risen by
24.05%
|
|
| Neuren Pharmaceuticals Limited (NEU) ORDINARY FULLY PAID |
Health Care |
$2,112 |
Notification of Neuren investor webinar on 12 February 2026
|
11 Feb 2026 5:05PM |
$13.430 |
$16.660 |
risen by
24.05%
|
|
| Neuren Pharmaceuticals Limited (NEU) ORDINARY FULLY PAID |
Health Care |
$2,112 |
Neuren to commence new on-market share buy-back program
|
11 Feb 2026 5:00PM |
$13.430 |
$16.660 |
risen by
24.05%
|
|
NEU - Price-sensitive ASX Announcement
Full Release
Key Points
- Neuren Pharmaceuticals Limited announced a new on-market share buy-back program.
- Shares purchased under the buy-back will be cancelled, reducing the number of shares on issue.
- The buy-back limit will adhere to the '10/12' rule under the Australian Corporations Act, not requiring shareholder approval.
- Neuren is developing therapies for serious neurological disorders.
- The company’s drugs, DAYBUE® and DAYBUE STIX, are FDA approved for Rett syndrome.
- Neuren's drug candidate, NNZ-2591, is in Phase 3 trials for Phelan-McDermid syndrome.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Neuren Pharmaceuticals Limited (NEU) ORDINARY FULLY PAID |
Health Care |
$2,112 |
First patient dosed in Neuren PMS Phase 3 trial
|
6 Feb 2026 9:26AM |
$13.200 |
$16.660 |
risen by
26.21%
|
|
NEU - Price-sensitive ASX Announcement
Full Release
Key Points
- First Phase 3 trial for Phelan-McDermid syndrome.
- Trial involves drug NNZ-2591.
- Randomized, double-blind, placebo-controlled study.
- Involves 160 children aged 3 to 12 years.
- Has FDA's Fast Track, Rare Pediatric Disease, and Orphan Drug designations.
- Strong community interest with 25 families referred and more on waitlists.
- Two sites activated, 20 more progressing in the US.
- Neuren is the Presenting Sponsor of the 2026 Phelan-McDermid Syndrome Foundation Family Conference.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Neuren Pharmaceuticals Limited (NEU) ORDINARY FULLY PAID |
Health Care |
$2,112 |
Priority Review Voucher program reauthorized by US Congress
|
5 Feb 2026 8:11AM |
$14.630 |
$16.660 |
risen by
13.88%
|
|
| Neuren Pharmaceuticals Limited (NEU) ORDINARY FULLY PAID |
Health Care |
$2,112 |
Neuren receives US FDA meeting feeback for HIE and PTHS
|
4 Feb 2026 5:07PM |
$14.630 |
$16.660 |
risen by
13.88%
|
|
NEU - Price-sensitive ASX Announcement
Full Release
Key Points
- Neuren received FDA feedback for NNZ-2591 development.
- Feedback provided as Written Responses Only and delayed.
- Clear path forward with minimal financial impact.
- For HIE, FDA accepted the clinical study plan but requested additional juvenile animal study data.
- For PTHS, FDA suggested using a PTHS-specific CGI scale with a functional outcome measure.
- Neuren plans to initiate the next trial in 2026.
- Progress in ongoing Koala Phase 3 trial for Phelan-McDermid syndrome.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Neuren Pharmaceuticals Limited (NEU) ORDINARY FULLY PAID |
Health Care |
$2,112 |
Trading Halt
|
4 Feb 2026 10:14AM |
$14.630 |
$16.660 |
risen by
13.88%
|
|
NEU - Price-sensitive ASX Announcement
Full Release
Key Points
- Neuren Pharmaceuticals Limited requested a trading halt starting 4 February 2026.
- The halt is in anticipation of an announcement concerning US FDA feedback on NNZ-2591.
- NNZ-2591 is being evaluated for Pitt Hopkins syndrome and Hypoxic-ischemic encephalopathy (HIE).
- The trading halt will lift by 6 February 2026 or upon the announcement.
- Neuren aims to manage disclosure obligations and ensure orderly market conditions.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Neuren Pharmaceuticals Limited (NEU) ORDINARY FULLY PAID |
Health Care |
$2,112 |
Pause in Trading
|
4 Feb 2026 9:57AM |
$14.630 |
$16.660 |
risen by
13.88%
|
|
NEU - Price-sensitive ASX Announcement
Full Release
Key Points
- Neuren Pharmaceuticals Limited has initiated a trading pause on ASX.
- The securities are traded under the code NEU.
- The pause is pending a future announcement.
- The action is a compliance measure by ASX Listings.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Neuren Pharmaceuticals Limited (NEU) ORDINARY FULLY PAID |
Health Care |
$2,112 |
Acadia provides update on EU regulatory submission
|
3 Feb 2026 9:40AM |
$16.250 |
$16.660 |
risen by
2.52%
|
|
NEU - Price-sensitive ASX Announcement
Full Release
Key Points
- Acadia Pharmaceuticals received a negative trend vote on trofinetide from CHMP.
- Acadia plans to request a re-examination of the CHMP opinion.
- Trofinetide is already approved in the US, Canada, and Israel.
- More than 1,000 patients are on active treatment with trofinetide globally.
- Neuren Pharmaceuticals supports the re-examination request.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Neuren Pharmaceuticals Limited (NEU) ORDINARY FULLY PAID |
Health Care |
$2,112 |
Response to ASX Aware Letter
|
19 Jan 2026 9:10AM |
$19.140 |
$16.660 |
fallen by
12.96%
|
|
NEU - Price-sensitive ASX Announcement
Full Release
Key Points
- NEU's announcement projected DAYBUE's global net sales to reach ~US$700m in 2028.
- The announcement led to a share price increase from $19.61 to $21.04.
- NEU confirmed the projection's material effect on securities' value.
- The projection's reasonableness was supported by ACAD's disclosures and NEU's internal models.
- NEU ensured compliance with ASX Listing Rules and confirmed immediate disclosure.
- NEU's Board authorized responses in line with continuous disclosure policy.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Neuren Pharmaceuticals Limited (NEU) ORDINARY FULLY PAID |
Health Care |
$2,112 |
DAYBUE net sales projected to reach approx US$700m in 2028
|
14 Jan 2026 10:26AM |
$19.930 |
$16.660 |
fallen by
16.41%
|
|
NEU - Price-sensitive ASX Announcement
Full Release
Key Points
- DAYBUE global net sales projected to reach ~US$700m in 2028
- More than 2,000 Rett patients treated since US launch in 2023
- DAYBUE STIX US launch in Q1 2026, full launch by Q2 2026
- DAYBUE oral solution approved in Israel
- Phase 3 trial of trofinetide in Japan with results expected Q4 2026/Q1 2027
- Neuren's focus on therapies for serious neurological disorders
- Exclusive worldwide license granted to Acadia for trofinetide
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Neuren Pharmaceuticals Limited (NEU) ORDINARY FULLY PAID |
Health Care |
$2,112 |
NNZ-2591 PMS Phase 2 trial published in Neurology Genetics
|
7 Jan 2026 10:20AM |
$18.990 |
$16.660 |
fallen by
12.27%
|
|
| Neuren Pharmaceuticals Limited (NEU) ORDINARY FULLY PAID |
Health Care |
$2,112 |
Health Canada approves Clinical Trial Application for Koala
|
22 Dec 2025 9:48AM |
$19.590 |
$16.660 |
fallen by
14.96%
|
|
| Neuren Pharmaceuticals Limited (NEU) ORDINARY FULLY PAID |
Health Care |
$2,112 |
FDA approves DAYBUE STIX (trofinetide), powder formulation
|
15 Dec 2025 9:05AM |
$19.010 |
$16.660 |
fallen by
12.36%
|
|
NEU - Price-sensitive ASX Announcement
Full Release
Key Points
- FDA approved DAYBUE STIX, a new powder formulation of trofinetide.
- DAYBUE STIX is designed for Rett syndrome patients aged two years and older.
- The new formulation offers flexible dosing options by mixing with liquids.
- Neuren Pharmaceuticals will receive royalties from the sales.
- Approval was based on bioequivalence with the original DAYBUE oral solution.
- DAYBUE STIX expected to be available in early 2026.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Call 1300 880 160
Start a chat
Schedule a call
